• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by VBI Vaccines Inc. New (Amendment)

    4/17/24 4:16:49 PM ET
    $VBIV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $VBIV alert in real time by email
    SC 13D/A 1 d816314dsc13da.htm SC 13D/A SC 13D/A

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

     

    SCHEDULE 13D/A

    THE SECURITIES EXCHANGE ACT OF 1934

    (Amendment No. 9)*

     

     

    VBI Vaccines Inc.

    (Name of Issuer)

    Common Shares, no par value per share

    (Title of Class of Securities)

    91822J 202

    (CUSIP Number)

    Alexander Rakitin

    Perceptive Advisors LLC

    51 Astor Place, 10th Floor

    New York, NY 10003

    (646) 205-5340

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

    April 16, 2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13D-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

     

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 91822J 202

     

     (1)   

     Name of reporting persons

     

     Perceptive Advisors LLC

     (2)  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☑

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds

     

     AF

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)   

     Sole voting power

     

     0

        (8)  

     Shared voting power

     

     1,261,710

        (9)  

     Sole dispositive power

     

     0

       (10)  

     Shared dispositive power

     

     1,261,710

     (11)   

     Aggregate amount beneficially owned by each reporting person

     

     1,261,710

     (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares*

     

     ☐

     (13)  

     Percent of class represented by amount in Row (11)

     

     4.4%

     (14)  

     Type of reporting person

     

     IA


    CUSIP No. 91822J 202

     

     (1)   

     Name of reporting persons

     

     Joseph Edelman

     (2)  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☑

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds

     

     AF

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     United States of America

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)   

     Sole voting power

     

     0

        (8)  

     Shared voting power

     

     1,261,710

        (9)  

     Sole dispositive power

     

     0

       (10)  

     Shared dispositive power

     

     1,261,710

     (11)   

     Aggregate amount beneficially owned by each reporting person

     

     1,261,710

     (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares*

     

     ☐

     (13)  

     Percent of class represented by amount in Row (11)

     

     4.4%

     (14)  

     Type of reporting person

     

     IN


    CUSIP No. 91822J 202

     

     (1)   

     Name of reporting persons

     

     Perceptive Life Sciences Master Fund, Ltd.

     (2)  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☑

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds

     

     WC

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     Cayman Islands

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)   

     Sole voting power

     

     0

        (8)  

     Shared voting power

     

     1,261,710

        (9)  

     Sole dispositive power

     

     0

       (10)  

     Shared dispositive power

     

     1,261,710

     (11)   

     Aggregate amount beneficially owned by each reporting person

     

     1,261,710

     (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares*

     

     ☐

     (13)  

     Percent of class represented by amount in Row (11)

     

     4.4%

     (14)  

     Type of reporting person

     

     CO


    CUSIP No. 91822J 202

     

     (1)   

     Name of reporting persons

     

     Perceptive Credit Holdings, LP

     (2)  

     Check the appropriate box if a member of a group

     (a) ☐  (b) ☐

     

     (3)  

     SEC use only

     

     (4)  

     Source of funds

     

     WC

     (5)  

     Check box if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

     

     ☐

     (6)  

     Citizenship or place of organization

     

     Delaware

    Number of

    shares

    beneficially 

    owned by

    each

    reporting

    person

    with

     

        (7)   

     Sole voting power

     

     0

        (8)  

     Shared voting power

     

     0

        (9)  

     Sole dispositive power

     

     0

       (10)  

     Shared dispositive power

     

     0

     (11)   

     Aggregate amount beneficially owned by each reporting person

     

     0

     (12)  

     Check box if the aggregate amount in Row (11) excludes certain shares*

     

     ☐

     (13)  

     Percent of class represented by amount in Row (11)

     

     0.0%

     (14)  

     Type of reporting person

     

     PN


    Item 5.

    Interest in Securities of the Issuer.

    Item 5 of the Schedule 13D is amended and supplemented as follows:

     

      (a)

    The information set forth in rows 11 and 13 of the cover pages to this Schedule 13D is incorporated by reference. The percentage set forth in row 13 is based on 28,432,275 outstanding Common Shares as reported by the Issuer in its Annual Report on Form 10-K filed with the Securities and Exchange Commission on April 16, 2024.

     

      (b)

    The information set forth in rows 7 through 10 of the cover pages to this Schedule 13D is incorporated by reference.

     

      (c)

    The Reporting Persons have not effected any transactions in the Issuer’s shares of Common Shares in the past 60-days.

     

      (d)

    Not applicable.

     

      (e)

    On April 16, 2024, the Reporting Persons ceased being holders of 5% or more of the outstanding shares of the Issuer’s Common Shares.


    SIGNATURE

    After reasonable inquiry and to the best of its knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

    Date: April 17, 2024

    PERCEPTIVE ADVISORS LLC

     

    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title:  Managing Member
    /s/ Joseph Edelman
    JOSEPH EDELMAN

    PERCEPTIVE LIFE SCIENCES MASTER FUND, LTD.

     

    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title:  Managing Member

    PERCEPTIVE CREDIT HOLDINGS, LP

     

    By:   Perceptive Advisors LLC
    By:   /s/ Joseph Edelman
      Name: Joseph Edelman
      Title:  Managing Member
    Get the next $VBIV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VBIV

    DatePrice TargetRatingAnalyst
    11/11/2022$5.00 → $2.00Strong Buy → Outperform
    Raymond James
    3/8/2022$9.00 → $6.00Strong Buy
    Raymond James
    12/29/2021$7.00 → $6.00Buy
    Jefferies
    More analyst ratings

    $VBIV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • VBI Vaccines Provides an Update on its Restructuring Proceedings

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today provided an update on the restructuring proceedings announced on July 30, 2024. U.S. Chapter 15 Filing On August 2, 2024, the United States Bankruptcy Court for the District of Delaware granted provisional relief under Chapter 15 of the U.S. Bankruptcy Code, and scheduled a further hearing to consider the recognition of the July 30, 2024, Ontario Superior Court of Justice (Commercial List) order ("Initial Order"), which granted the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("C

      8/2/24 4:05:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives

      VBI Vaccines Inc. (NASDAQ:VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the Ontario Superior Court of Justice (Commercial List) ("Court") has issued an initial order ("Initial Order") granting the company protection under the Companies' Creditors Arrangement Act, R.S.C. 1985, c. C-36, as amended ("CCAA"). The Initial Order provides for, among other things: (i) a stay of proceeding in favour of VBI, (ii) approval of the DIP Loan (as described below), and (iii) the appointment of Ernst & Young Inc. ("EY") to serve as monitor ("Monitor") in the Court during the restructuring ("Restructuring Pro

      7/30/24 9:55:00 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Announces Results of Annual General Meeting

      VBI Vaccines Inc. (NASDAQ:VBIV) ("VBI" or the "Company"), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the "Meeting"). The total number of common shares of the Company ("Common Shares") represented by shareholders ("Shareholders") present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI's issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024. The voting results with respect to each of the following eight dir

      6/25/24 4:15:00 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $VBIV
    SEC Filings

    See more
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      8/2/24 4:05:34 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Bankruptcy or Receivership, Creation of a Direct Financial Obligation, Other Events

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      7/30/24 10:28:18 AM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • VBI Vaccines Inc. New filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits

      8-K - VBI Vaccines Inc/BC (0000764195) (Filer)

      6/25/24 4:15:17 PM ET
      $VBIV
      Biotechnology: Pharmaceutical Preparations
      Health Care